Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL

NCT06658925 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
HSCT
Tyrosine Kinase Inhibitor

Interventions

DRUG: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.

Sponsor

Institute of Hematology & Blood Diseases Hospital, China